Oxurion will carry out an interim analysis of a phase 2 trial of its last remaining clinical asset – THR-149 for diabetic macular oedema (DME) – before the end of this year as it tries to g
Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial.
Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus,
